Evidence map›Paper›PMID 30059514›Full record

ArticlePloS one2018

Multimerization results in formation of re-bindable metabolites: A proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expression.

Dominik Summer, Andrea Kroess, Rudolf Woerndle, Christine Rangger, Maximilian Klingler, Hubertus Haas, Leopold Kremser, Herbert H Lindner, Elisabeth von Guggenberg, Clemens Decristoforo

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Dominik SummerDepartment of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Andrea KroessDepartment of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Rudolf WoerndleDepartment of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Christine RanggerDepartment of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Maximilian KlinglerDepartment of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Hubertus HaasDivision of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Leopold KremserDivision of Clinical Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck Austria.
Herbert H LindnerDivision of Clinical Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck Austria.
Elisabeth von GuggenbergDepartment of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0003-4944-4705
Clemens DecristoforoDepartment of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0003-0566-4036
Innsbruck Medical University · AT

Funding

Austrian Science Fund FWF P 25899Austrian Science Fund FWF P 25899-B23
6 · The paper itself

Abstract

Positron emission tomography (PET) with radiolabelled peptide-based tracers has attracted great interest in oncology over the past decades. The success of imaging is closely related to sufficient uptake of the radiotracer in malignant tissue and for this sufficient biological half-life, particularly in the bloodstream, is mandatory. Fast enzymatic degradation during circulation leading to insufficient imaging abilities of peptide-based radioligands remains a major issue. The design of multimeric constructs, bearing multiple targeting moieties, has been widely applied to improve target interaction. This concept may also be applied to prolong the biological half-life of peptide-based radiopharmaceuticals as enzymatic degradation can result in formation of metabolites still capable to interact with the target binding site. In this study we aimed to identify such metabolites and therefore we utilized the siderophore-based bifunctional chelator fusarinine C (FSC) for the design of novel mono- and multimeric constructs, bearing minigastrin (MG) analogues as targeting moieties to address cholecystokinin-2 receptors (CCK2R) which are overexpressed in a variety of cancerous diseases and are well known for fast enzymatic degradation, particularly for truncated des-(Glu)5-MG members, such as MG11. FSC-based imaging probes were radiolabelled with gallium-68 and characterized in vitro (logD, protein binding, affinity and cell-uptake studies, stability and metabolite studies, as well as generation of corresponding metabolites by artificial enzymatic degradation) and in vivo (biodistribution in A431-CCK2R/A431-mock tumour xenografted BALB/c nude mice and stability in blood of living BALB/c mice and analysis of corresponding organ homogenates and urine to identify degradation products). In summary, multimerization was accompanied by partial improvement towards targeting abilities. Identified metabolites formed by artificial enzymatic cleavage of trimeric FSC-MG conjugates in vitro contained intact binding sequences for the receptor. Furthermore, the 68Ga-labelled trimers exhibiting increasing uptake of radioligand in tumour tissue over time and improved in vivo stability in blood samples of living animals of the trimers compared to corresponding mono- and dimers, strongly supporting our hypothesis.

Indexed as

GastrinsRadiopharmaceuticalsAnimalsCell Line, TumorChelating AgentsFemaleFerric CompoundsGallium RadioisotopesHumansHydroxamic AcidsKidneyLiverMice, Inbred BALB CMice, NudeMolecular ImagingNeoplasm TransplantationChelating AgentsFerric CompoundsfusigenGallium RadioisotopesGastrinsHydroxamic AcidsminigastrinRadiopharmaceuticalsReceptor, Cholecystokinin B

Identifiers

PMID30059514
PMCPMC6066219
OpenAlexW2886385311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.